Poster 79 - Once-Daily Valbenazine Improves the Impacts and Symptoms of Tardive Dyskinesia in Patients: Results From the Phase 4 KINECT-PRO™ Study
Tuesday, April 28, 2026
12:30 PM - 1:00 PM MDT
Location: Screen 8, Exhibit Hall Poster Pavilion
Once-daily valbenazine is approved for the treatment of tardive dyskinesia (TD) and Huntington’s disease chorea. KINECT-PRO™ is the first clinical trial to comprehensively assess and report the effects of an approved TD medication using 3 validated patient-reported outcomes (PROs) as primary endpoints and subgroups categorized by psychiatric diagnosis or TD movement severity. This 24-week study demonstrated robust improvements in TD impacts and TD symptoms, both overall and in all subgroups.
Learning Objectives:
To understand physical and socio-emotional impacts of tardive dyskinesia (TD) in all patients, including those with a mood disorder and those with milder TD movement severity
To become familiar with the effects of once-daily valbenazine on several validated, patient-reported, quality-of-life measures and on TD movement severity
To recognize the benefits of administering patient-reported outcomes alongside clinician-reported outcomes in clinical studies of TD
